Key facts
- Summit Therapeutics announced data from its Phase II AK112-206 trial.
- The trial investigated AK112 in patients with non-small cell lung cancer.
Summit Therapeutics has released data from its Phase II AK112-206 clinical trial. This trial was designed to evaluate the effectiveness of AK112 in patients suffering from non-small cell lung cancer. Further details regarding the specific outcomes and implications of the data were not immediately available in the announcement.